Dr. Elliott Sigal is a former Executive Vice President and Director of Bristol-Myers Squibb, and served as Chief Scientific Officer and President of R&D for BMS from 2004 until 2013. He was a principal architect of BMS’ successful Biopharma Transformation Strategy and was instrumental in increasing R&D productivity, developing BMS’ strategy in biologics and acquiring external innovation in Bristol’s String of Pearls initiative. Among his accomplishments in various therapeutic areas was building BMS research into a lead position in the promising area of immuno-oncology. Under his leadership, fourteen new medicines for a broad range of therapeutic indications have come to market, including the major blockbusters Sprycel (Leukemia), Eliquis (Anticoagulant), Orencia (Rheumatoid Arthritis) and Yervoy, the first approved immune checkpoint inhibitor for cancer immunotherapy. Dr. Sigal currently serves as a Venture Partner and Senior Advisor to the healthcare team of New Enterprise Associates and is a member of the Board of Directors for the Mead Johnson Nutrition Company, Spark Therapeutics, Adaptimmune and the Melanoma Research Alliance. Dr. Sigal received his M.D. from the University of Chicago and trained in Internal Medicine and Pulmonary Medicine at the University of California, San Francisco. Prior to medical school he studied engineering at Purdue University, where he received a B.S., M.S., and Ph.D.
Mr. Holtzman has been a leading entrepreneur and executive in the biotechnology field since the mid-1980s. Currently, Mr. Holtzman serves as the President and CEO Decibel Therapeutics. Prior to that, he was the Executive Vice President, Corporate Development of Biogen Inc. Previously, he served as the founder, CEO and Chairman of the Board of Directors of Infinity Pharmaceuticals, Inc., and the Chief Business Officer of Millennium Pharmaceuticals, Inc. In addition, Mr. Holtzman was a founder, member of the Board and the Executive Vice President of DNX Corporation. Currently, he is a member of the boards of directors of PMV Pharma, Visterra and Molecular Partners. In the not-for-profit arena, Mr. Holtzman is a Trustee of the Berklee College of Music, and previously served as the Vice Chairman of the Board of Trustees of the Hastings Center for Ethics and the Life Sciences and as a Presidential appointee to the US National Bioethics Advisory Commission. He received his B.A. in Philosophy from Michigan State University and his B.Phil. graduate degree in Philosophy from Corpus Christi College, Oxford University, which he attended as a Rhodes Scholar.